Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab
RNA-seq (gene expression) · human · 76 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 76 samples: 23 × C1D vs 23 × C2D vs 19 × C3D vs 11 × C4DGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with NivolumabClinical cancer research : an official journal of the American Association for Cancer Research · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE302752_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1292104 and SRA study SRP601192. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 76 samples.
How we read this: 4 replicated groups read from 76 sample titles; they account for 76 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9110790 INTRUST_07, timepoint: C1D1 C1D
- GSM9110791 INTRUST_07, timepoint: C2D1 C2D
- GSM9110792 INTRUST_07, timepoint: C3D1 C3D
- GSM9110793 INTRUST_07, timepoint: C4D1 C4D
- GSM9110794 INTRUST_08, timepoint: C1D1 C1D
- GSM9110795 INTRUST_08, timepoint: C2D1 C2D
- GSM9110796 INTRUST_08, timepoint: C4D1 C4D
- GSM9110797 INTRUST_08, timepoint: C3D1 C3D
- GSM9110798 INTRUST_09, timepoint: C1D1 C1D
- GSM9110799 INTRUST_09, timepoint: C2D1 C2D
- GSM9110800 INTRUST_09, timepoint: C4D1 C4D
- GSM9110801 INTRUST_09, timepoint: C3D1 C3D
- GSM9110802 INTRUST_10, timepoint: C1D1 C1D
- GSM9110803 INTRUST_10, timepoint: C4D1 C4D
- GSM9110804 INTRUST_10, timepoint: C2D1 C2D
- GSM9110805 INTRUST_10, timepoint: C3D1 C3D
- GSM9110806 INTRUST_11, timepoint: C1D1 C1D
- GSM9110807 INTRUST_11, timepoint: C3D1 C3D
- GSM9110808 INTRUST_11, timepoint: C2D1 C2D
- GSM9110809 INTRUST_12, timepoint: C3D1 C3D
- GSM9110810 INTRUST_12, timepoint: C2D1 C2D
- GSM9110811 INTRUST_13, timepoint: C1D1 C1D
- GSM9110812 INTRUST_13, timepoint: C2D1 C2D
- GSM9110813 INTRUST_13, timepoint: C3D1 C3D
- GSM9110814 INTRUST_14, timepoint: C1D1 C1D
- GSM9110815 INTRUST_14, timepoint: C2D1 C2D
- GSM9110816 INTRUST_15, timepoint: C2D1 C2D
- GSM9110817 INTRUST_15, timepoint: C3D1 C3D
- GSM9110818 INTRUST_15, timepoint: C4D1 C4D
- GSM9110819 INTRUST_16, timepoint: C1D1 C1D
- GSM9110820 INTRUST_16, timepoint: C2D1 C2D
- GSM9110821 INTRUST_17, timepoint: C3D1 C3D
- GSM9110822 INTRUST_17, timepoint: C2D1 C2D
- GSM9110823 INTRUST_17, timepoint: C1D1 C1D
- GSM9110824 INTRUST_18, timepoint: C2D1 C2D
- GSM9110825 INTRUST_18, timepoint: C1D1 C1D
- GSM9110826 INTRUST_18, timepoint: C3D1 C3D
- GSM9110827 INTRUST_18, timepoint: C4D1 C4D
- GSM9110828 INTRUST_19, timepoint: C2D1 C2D
- GSM9110829 INTRUST_19, timepoint: C1D1 C1D
+ 36 more — browse all 76 samples with per-sample file links →
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares 4-1bb, combination
- GSE302453 A single-cell map of intratumoral heterogeneity during combination treatment of anti-PD1 and chemotherapy in triple-negative breast cancer 2 samples shares intratumoral, combination
- GSE324815 Intratumoral CD40 agonist sotigalimab in combination with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: Results of a phase 1/2 study 24 samples shares intratumoral, combination
- GSE310962 EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy 8 samples shares intratumoral, combination
- GSE254547 RNA sequencing comparison of B7-H3.TMIGD2 and B7-H3.CD28.4-1BB CAR-T cells 28 samples shares 4-1bb
- GSE267821 4-1BB causes CAR-T cell death via sequestration of the ubiquitin-modifying enzyme A20 22 samples shares 4-1bb
- GSE276932 Gene expression in self-activating CAR-T cells with CD28 or 4-1BB costimulatory domain and G4S or Whilow218 linker. 15 samples shares 4-1bb
- GSE254546 RNA sequencing comparison of B7-H3.TMIGD2 and B7-H3.CD28.4-1BB CAR-T cells to CD19.CD28.4-1BB CAR-T cells in vitro 12 samples shares 4-1bb
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.